A 41-gene signature derived from breast cancer stem cells as a predictor of survival

Journal of Experimental and Clinical Cancer Research

Volumn 33, Issue 1, 2014, Pages

  Yin, Zhi Qiang ^a   Liu, Jian Jun ^a   Xu, Ying Chun ^a   Yu, Jian ^b   Ding, Guo Hui ^b   Yang, Feng ^a   Tang, Lei ^a   Liu, Bao Hong ^b   Ma, Yue ^a   Xia, Yu Wei ^a   Lin, Xiao Lin ^a   Wang, Hong Xia ^a,c  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANGHAI CENTER FOR BIOINFORMATION TECHNOLOGY   (China)

^c SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Breast cancer; Prognostic signature; Stem cell

Indexed keywords

ESTROGEN RECEPTOR;

AGE; ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER PROGNOSIS; CANCER STEM CELL; CANCER SURVIVAL; DISTANT METASTASIS FREE SURVIVAL; FEMALE; GENE EXPRESSION PROFILING; HUMAN; METASTASIS; OVERALL SURVIVAL; TREATMENT OUTCOME; TUMOR GENE; BREAST TUMOR; GENETICS; PATHOLOGY; PERSONALIZED MEDICINE; PHYSIOLOGY; PROCEDURES; PROGNOSIS; SURVIVAL;

BREAST NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; INDIVIDUALIZED MEDICINE; NEOPLASM METASTASIS; NEOPLASTIC STEM CELLS; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 84908054563     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-33-49     Document Type: Article

References (29)

1. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, Talantov D, Timmermans M, Meijer-van Gelder ME, Yu J, Jatkoe T, Berns EM, Atkins D, Foekens JA, Lancet 2005 365 671 679
2. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: Clinical practice guidelines of the American Society of Clinical Oncology. Bast RC Jr, Ravdin P, Hayes DF, Bates S, Fritsche H Jr, Jessup JM, Kemeny N, Locker GY, Mennel RG, Somerfield MR, J Clin Oncol 2001 19 1865 1878
3. Meta-analysis of human lung cancer microRNA expression profiling studies comparing cancer tissues with normal tissues. Peng G, Zhihua Y, Xuelian L, Wei W, Baosen Z, JECCR 2012 31 54
4. Performance of common genetic variants in breast-cancer risk models. Wacholder S, Hartge P, Prentice R, Garcia-Closas M, Feigelson HS, Diver WR, Thun MJ, Cox DG, Hankinson SE, Kraft P, Rosner B, Berg CD, Brinton LA, Lissowska J, Sherman ME, Chlebowski R, Kooperberg C, Jackson RD, Buckman DW, Hui P, Pfeiffer R, Jacobs KB, Thomas GD, Hoover RN, Gail MH, Chanock SJ, Hunter DJ, N Engl J Med 2010 362 886 893
5. The prognostic contribution of clinical breast cancer subtype, age, and race among patients with breast cancer brain metastases. Anders CK, Deal AM, Miller CR, Khorram C, Meng H, Burrows E, Livasy C, Fritchie K, Ewend MG, Perou CM, Carey LA, Cancer 2011 8 1602 1611
6. Breast cancer tumor size, nodal status, and prognosis: biology trumps anatomy. Comen EA, Norton L, J Clin Oncol 2011 23 2610 2612
7. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Ma XJ, Wang Z, Ryan PD, Isakoff SJ, Barmettler A, Fuller A, Muir B, Mohapatra G, Salunga R, Tuggle JT, Tran Y, Tran D, Tassin A, Amon P, Wang W, Wang W, Enright E, Stecker K, Estepa-Sabal E, Smith B, Younger J, Balis U, Michaelson J, Bhan A, Habin K, Baer TM, Brugge J, Haber DA, Erlander MG, Sgroi DC, Cancer Cell 2004 5 607 616
8. Manganese superoxide dismutase and breast cancer recurrence: a Danish clinical registry-based case-control study, and a meta-analysis. Cronin-Fenton DP, Christensen M, Lash TL, Ahern TP, Pedersen L, Garne JP, Ewertz M, Autrup H, Sørensen HT, Hamilton-Dutoit S, PLoS One 2014 9 87450
9. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. O'Brien CA, Pollett A, Gallinger S, Dick JE, Nature 2006 445 106 110
10. Identification and expansion of human colon-cancer-initiating cells. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, De Maria R, Nature 2006 445 111 115
11. Cancer stem cells: models and concepts. Dalerba P, Cho RW, Clarke MF, Annual Rev Med 2007 58 267 284
12. Cause-specific telomere factors deregulation in hepatocellular carcinoma. Manale El I, Valérie H, Philippe M, Franck M, Eric W, JECCR 2013 32 64
13. Global profiling of signaling networks: study of breast cancer stem cells and potential regulation. Wang H, Huang M, Zhang DY, Zhang F, Oncologist 2011 16 966 979
14. Effect of fibroblasts on breast cancer cell mammosphere formation and regulation of stem cell-related gene expression. Zhang F, Song C, Ma Y, Tang L, Xu Y, Wang H, Int J Mol Med 2011 28 365 371
15. The logrank test. Bland JM, Altman DG, BMJ 2004 328 1073
16. Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Desmedt C, Piette F, Loi S, Wang Y, Lallemand F, Haibe-Kains B, Viale G, Delorenzi M, Zhang Y, d'Assignies MS, Bergh J, Lidereau R, Ellis P, Harris AL, Klijn JG, Foekens JA, Cardoso F, Piccart MJ, Buyse M, Sotiriou C, Clin Cancer Res 2007 13 3207 3214
17. A gene-expression signature as a predictor of survival in breast cancer. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernards R, N Engl J Med 2002 347 1999 2009
18. Gene-expression signatures in breast cancer. Sotiriou C, Phil D, N Engl J Med 2009 360 790 800
19. A tiny step closer to personalized risk prediction for breast cancer. Devilee P, Rookus MA, N Engl J Med 2010 362 1043 1045
20. Osteopontin genetic variants are associated with overall survival in advanced non-small-cell lung cancer patients and bone metastasis. Yunzhen C, Haichun L, Wenliang W, Yi L, Jianmin L, JECCR 2013 32 45
21. Metastatic behavior of breast cancer subtypes. Kennecke H, Yerushalmi R, Woods R, Cheang MC, Voduc D, Speers CH, Nielsen TO, Gelmon K, J Clin Oncol 2010 28 3271 3277
22. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, Cronin M, Baehner FL, Watson D, Bryant J, Costantino JP, Geyer CE Jr, Wickerham DL, Wolmark N, J Clin Oncol 2006 24 3726 3734
23. Molecular portraits of human breast tumors. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lønning PE, Børresen-Dale AL, Brown PO, Botstein D, Nature 2000 406 747 752
24. Concise review: transmissible animal tumors as models of the cancer stem-cell process. O'Neill JD, Stem Cells 2011 29 1909 1914
25. CD44 isoforms are heterogeneously expressed in breast cancer and correlate with tumor subtypes and cancer stem cell markers. Olsson E, Honeth G, Bendahl PO, Saal LH, Gruvberger-Saal S, Ringnér M, Vallon-Christersson J, Jönsson G, Holm K, Lövgren K, Fernö M, Grabau D, Borg A, Hegardt C, BMC Cancer 2011 11 418
26. Cancer stem cell niche: the place to be. Borovski T, De Sousa E, Melo F, Vermeulen L, Medema JP, Cancer Res 2011 71 634 639
27. Cancer stem cells. Jordan CT, Guzman ML, Noble M, N Engl J Med 2006 355 1253 1261
28. Gene expression profiling predicts clinical outcome of breast cancer. Veer LJ V 't, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH, Nature 2002 415 530 536
29. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J, Wolmark N, N Engl J Med 2004 351 2817 2826